Sensei Biotherapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Sensei Biotherapeutics seeks stockholder approval for post-acquisition governance, share authorization, and equity plans following its merger with Faeth Therapeutics.
NASDAQ
Sensei Biotherapeutics has filed a definitive proxy statement with the SEC.
NASDAQ
Sensei Biotherapeutics is seeking stockholder approval for a reverse stock split to increase its stock price and maintain its Nasdaq listing.
NASDAQ
Sensei Biotherapeutics will hold its annual stockholders meeting on June 11, 2024, to elect directors and ratify the selection of Deloitte & Touche LLP as its independent accounting firm.
NASDAQ
Sensei Biotherapeutics will hold its annual stockholders meeting virtually on June 11, 2024, to elect directors and ratify the selection of its independent accounting firm.